



BIODIEM LTD
ABN 20 096 845 993
Level 4,
100 Albert Rd,
South Melbourne, Victoria, 3205
Australia
Phone: +613 9692 7240
Web: www.biodiem.com

Announcement

Appointment of Prof Li to the BioDiem Board

Melbourne, 22 January 2016:

BioDiem Ltd is pleased to announce the appointment of Professor Arthur Li, as a non-executive director, to the BioDiem board. Prof Li was previously a director of BioDiem from 2010 until 2014.

Professor Li obtained his degree of Doctor of Medicine from the University of Cambridge. He is the Emeritus Professor of Surgery of the Chinese University of Hong Kong. He is the Deputy Chairman of the Bank of East Asia Limited and a member of the Chinese People's Political Consultative Conference. Professor Li was Professor of Surgery and Chairman of the Department of Surgery, Dean of the Faculty of Medicine and Vice-Chancellor at the Chinese University of Hong Kong. He was the Secretary for Education and Manpower, and a member of the Executive Council of the Hong Kong Special Administrative Region Government from 2002 to 2007. Professor Li was awarded a Gold Bauhinia Star in 2000. Professor Li is Council Chairman of University of Hong Kong. He is also Chairman of the Council for Sustainable Development of the Government of HKSAR.

Professor Li's brother, Sir David K.P. Li is a major shareholder of BioDiem Ltd.

- ENDS -

About BioDiem Ltd

BioDiem is an Australian biopharmaceutical company that is focused on developing and commercialising vaccines and infectious disease therapies. BioDiem's business model is to generate income from partnerships including with other vaccine and infectious disease treatment companies through existing and new licences to its LAIV vaccine and other technologies. Income comes from licence fees and royalties on sales.

BioDiem's lead technology is the LAIV (Live Attenuated Influenza Virus) vaccine technology used for production of seasonal and pandemic influenza vaccines and is given intranasally. This technology is licensed currently to two commercial partners, in India and China, and is licenced to the World Health Organisation as part of the Global Pandemic Influenza Action Plan to Increase Vaccine Supply. Serum Institute of India's Nasovac-S™ is based on BioDiem's technology and is already marketed in India.

BioDiem's antimicrobial technology, BDM-I, is being developed through its subsidiary, Opal Biosciences Ltd. For additional information, please visit www.biodiem.com.

About Opal Biosciences Ltd

Opal Biosciences is an Australian biotechnology company and an innovative player in infectious disease

treatment. The unmet need for new anti-infectives is due to increasing resistance to existing antibiotics, more widespread and common difficult-to-treat infections, and the paucity of upcoming new treatments. This need has spurred the EU and US to introduce significant financial incentives to encourage development of new anti-infectives. Opal is currently seeking funding to support the next stage of development of our products:

- Opal-I, an injectable product, and
- Opal-T, which can be applied to the skin.

For more information, please visit www.opalbiosciences.com.